Assessment of biomarkers of cardiovascular risk among HIV type 1-infected adolescents: Role of soluble vascular cell adhesion molecule as an early indicator of endothelial inflammation

AIDS Research and Human Retroviruses

Volumn 29, Issue 3, 2013, Pages 493-500

  Syed, Salma S ^a   Balluz, Rula S ^b   Kabagambe, Edmond K ^c   Meyer, William A ^d   Lukas, Susan ^e   Wilson, Craig M ^c   Kapogiannis, Bill G ^f   Nachman, Sharon A ^a   Sleasman, John W ^e  

^a STONY BROOK UNIVERSITY   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

^f EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; BIOLOGICAL MARKER; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MYELOPEROXIDASE; NEOPTERIN; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1; VERY LOW DENSITY LIPOPROTEIN;

ADOLESCENT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFLAMMATION; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; SMOKING; T LYMPHOCYTE SUBPOPULATION; VIRUS LOAD; VIRUS REPLICATION;

EID: 84874505795     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0086     Document Type: Article

References (38)

1. Grinspoon SK, et al.: State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: Executive summary. Circulation 2008;118(2):198-210.
2. Triant VA, et al.: Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007;92(7):2506-2512.
3. Currier JS, et al.: Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003;33(4):506-512.
4. Grunfeld C, et al.: Preclinical atherosclerosis due to HIV infection: Carotid intima-medial thickness measurements from the FRAM study. AIDS 2009;23(14):1841-1849.
5. Kapogiannis BG, et al.: Introduction: Paving the way for biomedical HIV prevention interventions in youth. J Acquir Immune Defic Syndr 2011;54(Suppl 1): S1-4.
6. Kruzich LA, et al.: HIV-infected US youth are at high risk of obesity and poor diet quality: A challenge for improving short- and long-term health outcomes. J Am Diet Assoc 2004;104(10):1554-1560.
7. Hakeem A, Bhatti S, and Cilingiroglu M: The spectrum of atherosclerotic coronary artery disease in HIV patients. Curr Atheroscler Rep 2011;12(2):119-124.
8. Crowe SM, et al.: The macrophage: The intersection between HIV infection and atherosclerosis. J Leukoc Biol 2011;87(4): 589-598.
9. Rogers AS, et al.: The REACH Project of the Adolescent Medicine HIV/AID Research Network: Design, methods, and selected characteristics of participants. J Adolesc Health 1998;22(4):300-311.
10. Kavey RE, Daniels SR, Lauer RM, Atkins DL, Hayman LL, Taubert K: American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. J Pediatr. 2003;142(4):368-372.
11. de Gaetano Donati K, et al.: Increased soluble markers of endothelial dysfunction in HIV-positive patients under highly active antiretroviral therapy. AIDS 2003;17(5):765-768.
12. Torriani FJ, et al.: Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol 2008;52(7):569-576.
13. Triant VA, Meigs JB, and Grinspoon SK: Association of Creactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr 2009;51(3):268-273.
14. Wolf K, et al.: Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 2002;185(4):456-462.
15. Murphy DA, et al.: Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care 2001;13(1):27-40.
16. Holland CA, et al.: Relationship of CD4+ T cell counts and HIV type 1 viral loads in untreated, infected adolescents. Adolescent Medicine HIV/AIDS Research Network. AIDS Res Hum Retroviruses 2000;16(10):959-963.
17. Rudy BJ, Crowley-Nowick PA, and Douglas SD: Immunology and the REACH study: HIV immunology and preliminary findings. Reaching for Excellence in Adolescent Care and Health. J Adolesc Health 2001;29(3 Suppl): 39-48.
18. Ridker PM, et al.: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347(20): 1557-1565.
19. Pearson TA, et al.: Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107(3): 499-511.
20. Riddler SA, et al.: Impact of HIV infection and HAART on serum lipids in men. JAMA 2003;289(22):2978-2982.
21. Aldrovandi GM, et al.: Morphologic and metabolic abnormalities in vertically HIV-infected children and youth. AIDS 2009;23(6):661-672.
22. Mulligan K, et al.: Obesity and dyslipidemia in behaviorally HIV-infected young women: Adolescent Trials Network study 021. Clin Infect Dis 2011;50(1):106-114.
23. Baker JV, et al.: Inflammation predicts changes in highdensity lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy. AIDS 2011;25(17): 2133-2142.
24. Fichtenbaum CJ, Does antiretroviral therapy increase or decrease the risk of cardiovascular disease? Curr HIV/AIDS Rep 2011;7(2):92-98.
25. Hansson GK and Libby P: The immune response in atherosclerosis: A double-edged sword. Nat Rev Immunol 2006;6(7):508-519.
26. Cybulsky MI, et al.: A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001;107(10): 1255-1262.
27. Francisci D, et al.: HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction. AIDS 2009;23(5): 589-596.
28. Miller T, et al.: Metabolic abnormalities and viral replication are associated with biomarkers of vascular dysfunction in HIV-infected children. HIV Med 2011;13(5):264-275.
29. Schecter AD, et al.: HIV envelope gp120 activates human arterial smooth muscle cells. Proc Natl Acad Sci USA 2001; 98(18):10142-10147.
30. Wagner DD: New links between inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2005;25(7):1321-1324.
31. Brenchley JM, et al.: Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12(12):1365-1371.
32. Wallet MA, et al.: Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy. AIDS 2011;24(9):1281-1290.
33. Ancuta P, et al.: Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One 2008;3(6):e2516.
34. Sandler NG, et al.: Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203(6):780-790.
35. Baier-Bitterlich G, Wachter H, and Fuchs D: Role of neopterin and 7,8-dihydroneopterin in human immunodeficiency virus infection: Marker for disease progression and pathogenic link. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13(2):184-193.
36. Fuchs D, et al.: The role of neopterin in atherogenesis and cardiovascular risk assessment. Curr Med Chem 2009;16(35): 4644-4653.
37. Brennan ML, et al.: Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003;349(17):1595-1604.
38. Ross AC, et al.: Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy. J Acquir Immune Defic Syndr 2008; 49(5): 499-506.